In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide is a glucagon-like-peptide 1 receptor agonist. The aim of our study is to present reliable and up-to-date knowledge of effects that both drugs provide and their beneficial effects on health.
No takes yet. Share an insight, caveat, or question.
Staroń et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: